期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雷帕霉素洗脱支架预防冠状动脉再狭窄的研究进展 被引量：1

Research advance on rapamycin-eluting stent in preventing coronary artery restenosis
暂未订购
导出
摘要 经皮冠状动脉介入治疗已成为治疗冠心病的重要手段之一 ,但术后再狭窄仍是介入心脏病学面临的难题。现论述雷帕霉素的一般药理特性和雷帕霉素洗脱支架预防再狭窄的基础研究、临床试验等方面的研究进展。 Percutaneous coronary interventions have been one of the important methods for treating coronary artery disease, but restenosis is still the difficult problem that interventional cardiology is confronted with. This article reviews some common pharmacological characters of rapamycin, advance of basic researches and clinical trials about rapamycin-eluting stent in preventing coronary restenosis. And also mentions the possible problems in this article.
作者 阳维德 郑萍
机构地区 广西壮族自治区南溪山医院心内科
出处 《华夏医学》 2004年第5期829-831,共3页 Acta Medicinae Sinica
关键词 经皮冠状动脉介入治疗 雷帕霉素 药物洗脱支架 再狭窄 percutaneous coronary interventions rapamycin drug eluting stent restenosis
分类号 R543.3 [医药卫生—心血管疾病]
  • 相关文献

参考文献25

  • 1[1]Sousa JE,Costa MA,Abizaid AC,et al.Sustained suppression of neointimal proliferation by sirolimus-eluting stents:one-year angiographic and intravascular ultrasound follow-up[J].Circulation,2001,104(17):2007-2011.
  • 2[2]Morice MC,Serruys PW,Sousa JE,et al.A randomized comparision of a sirolimus-eluting stent with a standard stent for coronary revascularization[J].N Engl J Med,2002,346(23):1773-1780.
  • 3[3]Moses JW,O'shaughnessy C,Caputo R,et al.The US multicenter,randomized,double-blind study of the sirolimus-eluting stent in coronary lesions:safety outcomes at 9 months[J].Eur Heart J,2002,23 (suppl):264.
  • 4[4]Holmes DR Jr,Leon MB,Moses JW,et al.Analysis of 1-year clinical in SIRIUS trial:a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high-risk for coronary restenosis[J].Circulation,2004,109(5):634-640.
  • 5[5]Grube E,Silber S,Hauptmann KE,Mueller R,et al.TAXUS I:Six-and twelve-month results from a randomized,double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions[J].Circulation,2003,107(1):38-42.
  • 6[6]Colomb A,Drzewiecki J,Banning A,et al.Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions[J].Circulation,2003,108(7):788-794.
  • 7[7]Tanabe K,Serruys PW,Grube E,et al.TAXUS Ⅲ Trial:in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation[J].Circulation,2003,107(4):559-564.
  • 8[8]Stone GW,Ellis SG,Cox DA,et al.One-year clinical results with the slow-release,polymer-based,paclitaxel-eluting TAXUS stent:the TAXUS-IV trial[J].Circulation,2004,109(16):1942-1947.
  • 9[9]Abranham RT,Wiederrecht GJ.Immunopharmacology of rapamycin[J].Annu Rev Immund,1996,14:483-510.
  • 10[10]Yatscoff RW,Wang P,Chan K,et al.Rapamycin:distribution,pharmacokinetics,and therapeutic range investigations[J].Ther Drug Monit,1995,17(6):666-671.

共引文献31

同被引文献16

  • 1Gruentzig AR, King SB, Schlumpf M, et al. Long-term fol- low-up after percutaneous transluminal coronary angio- plasty. The early Zurich experience [J]. N Engl J Med, 1987, 316(18): 1127-1132.
  • 2Kang S J, Mintz GS, Park DW, et al.Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravascular ultrasound analysis [J]. Circ Cardiovasc In- terv, 2011,4( 1 ):9-14.
  • 3David Holmes, Martin B Leon, Jeffrey W Moses, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a stan- dard stent in patients at high risk for coronary restenosis E J]. Circulation,2004,109 (5) :634-640.
  • 4Ole Frobert, Bo Layerqvist, Jorg Carlsson, et al. Differenc- es in restenosis rate with different drug-eluting stents in pa- tients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Regis try) [J]. JAm Coll Cardiol, 2009, 53( 18): 1660-1667.
  • 5Wang L, Rhodes CJ , Lawrence JcJr. Activation of mam- malian target of rapamycin (mTOR) by insulin is associat- ed with stimulation of 4EBP1 binding to dimeric mTOR complex 1 [J]. J Biol Chem, 2006, 281 (34):24293-24303.
  • 6Fingar DC, Salama S, Tsou C, etal. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4EIJ]. Genes Dev, 2002,16( 12): 1472-1487.
  • 7Lamming D, Ye L, Katajisto P, etal. Rapamycin-induced in- sulin resistance is mediated by mTORC2 loss and uncoupled from longevityE J]. Science, 2012, 335(6076): 1638-1643.
  • 8Pasini E, Flati V, Paiardi Set al. Intracellular molecular ef- fects of insulin resistance in patients with metabolic syn- drome[J]. Cardiovasc Diabetol, 2010, 9:46.
  • 9Breen DM, Giacca A. Effects of insulin on the vasculature [J]. Curr Vasc Pharmacol, 2011, 9(3): 321-332.
  • 10Rask-Madsen C, Li Q, Freund B, et al. Loss of insulin sig- naling in vascular endothelial cells accelerates atheroscle- rosis in apolipoprotein E null mice [J]. Cell Metab, 2010, 11(5): 379-389.

二级引证文献3

华夏医学
2004年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部